Biotechs inhabit their own universe within the stock market. Prone to huge upward or downward swings dependent on positive or negative news flow. They are also in a unique position when earnings season comes around as clinical-stage biopharmas usually do not generate any revenue. When these companies report the quarter’s financials, investors are mostly interested in two issues. One, does the company have the necessary funds to continue its pipeline’s development? And two, any updates regarding said pipeline’s progress. Following Atossa Therapeutics’ (ATOS) Q2 earnings, Maxim’s Jason McCarthy thinks the company is well positioned on both fronts.
https://www.tipranks.com/news/article/atossa-strong-balance-sheet-will-support-the-pipelines-advance-says-analyst?utm_source=advfn.com&utm_medium=referral
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Atossa Therapeutics Charts.
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Atossa Therapeutics Charts.